Kappa Opioids, Salvinorin A and Major Depressive Disorder.

Opioids, long known for pain and addiction, are now recognized as central to mood regulation, potentially shifting focus from monoamine neurotransmitters to opioid systems in depression. Dynorphin, the last major endogenous opioid discovered, and its kappa receptor have distinct, often opposite effects from mu-receptor opioids like beta-endorphin and morphine. This review examines dynorphin/kappa neurobiology in relation to major depressive disorder (MDD). Salvinorin A, a plant-based kappa agonist, shows a complex pharmacological profile beyond kappa agonism, making it a promising candidate for MDD treatment research.

Study at a glance

Abstract

Opioids are traditionally associated with pain, analgesia and drug abuse. It is now clear, however, that the opioids are central players in mood. The implications for mood disorders, particularly clinical depression, suggest a paradigm shift from the monoamine neurotransmitters to the opioids either alone or in interaction with monoamine neurons. We have a special interest in dynorphin, the last of the major endogenous opioids to be isolated and identified. Dynorphin is derived from the Greek word for power, dynamis, which hints at the expectation that the neuropeptide held for its discoverers. Yet, dynorphin and its opioid receptor subtype, kappa, has always taken a backseat to the endogenous b-endorphin and the exogenous morphine that both bind the mu opioid receptor subtype. That may be changing as the dynorphin/ kappa system has been shown to have different, often opposite, neurophysiological and behavioral influences. This includes major depressive disorder (MDD). Here, we have undertaken a review of dynorphin/ kappa neurobiology as related to behaviors, especially MDD. Highlights include the unique features of dynorphin and kappa receptors and the special relation of a plant-based agonist of the kappa receptor salvinorin A. In addition to acting as a kappa opioid agonist, we conclude that salvinorin A has a complex pharmacologic profile, with potential additional mechanisms of action. Its unique neurophysiological effects make Salvinorina A an ideal candidate for MDD treatment research.